Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 13/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31499183 | 1.00 | PDCD1 (0.48) | PDCD1CD274ALDH1A1TSHRMEN1 | |
| SCHEMBL19897782 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TSHRMEN1LMNATHRB | |
| SCHEMBL30395616 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TSHRMEN1LMNATHRB | |
| SCHEMBL27539947 | 0.84 | ALDH1A1 (0.43) | PDCD1CD274ALDH1A1TSHRMEN1 | |
| SCHEMBL6979126 | 0.84 | KCNJ1 (0.46) | PDCD1CD274ALDH1A1TSHRMEN1 | |
| SCHEMBL27681523 | 0.83 | ALDH1A1 (0.53) | PDCD1CD274ALDH1A1TSHRMEN1 | |
| SCHEMBL18367731 | 0.83 | ERN1 (0.41) | PDCD1CD274ALDH1A1TSHRMEN1 | |
| SCHEMBL31620987 | 0.81 | PDCD1 (0.51) | PDCD1CD274 | |
| SCHEMBL5711323 | 0.81 | LMNA (0.57) | ALDH1A1TSHRMEN1LMNATHRB | |
| SCHEMBL96494 | 0.81 | LMNA (0.57) | ALDH1A1TSHRMEN1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011123-A | A kind of method of catalytic hydrogen reduction 2-methyl-3-biphenylmethanol | 江苏科菲特生化技术股份有限公司 | 2017-08-04 | — | — | CN | claimed |
| CN-101704723-B | Preparation method of hydroxymethyl substitutent o-alkyl biphenyl and intermediate thereof | SHANGHAI WANSU CHEMICAL CO LTD | 2013-04-24 | — | — | CN | claimed |
| CN-101704723-A | Preparation method of hydroxymethyl substitutent o-alkyl biphenyl and intermediate thereof | SHANGHAI WANSU CHEMICAL CO LTD | 2010-05-12 | — | — | CN | claimed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| CN-119136802-A | Adenosine 2A receptor modulators for the treatment of cancer | 瑞士日内瓦大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-116768779-B | Small molecular compound as immunomodulator, and composition and application thereof | 齐鲁师范学院 | 2024-04-02 | — | — | CN | disclosed |
| CN-116874405-B | Indole compound as immunomodulator and preparation method and application thereof | 山东轩硕医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| CN-116874405-A | Indole compound as immunomodulator and preparation method and application thereof | 山东轩硕医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1392643-A2 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002094767-A2 | TRISUBSTITUTED-N-[(1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LABORATORIES (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | ABBOTT LABORATORIES | 2002-11-21 | — | — | US | disclosed |
| EP-0674620-A1 | TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| CN-1092765-A | New tryptamine analogues and preparation method thereof and purposes | SMITHKLINE BEECHAM PLC (GB) | 1994-09-28 | — | — | CN | disclosed |
| WO-1994014771-A1 | TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | PDCD1 3505/4885CD274 3696/4885ALDH1A1 404/4885 |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | PDCD1 384/4885CD274 216/4885ALDH1A1 2193/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | PDCD1 3/4885CD274 1/4885ALDH1A1 1759/4885 |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | PDCD1 3344/4885CD274 3316/4885ALDH1A1 392/4885 |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885ALDH1A1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.